D. Fyfe
Impact in
- Internal Medicine top 2%
- Venous Thromboembolism Diagnosis and Management
- Biochemistry top 5%
- Phytochemicals and Antioxidant Activities
Papers in
- Co-authors
- D. Ferry (3 shared papers)J Baker (1 shared paper)Adam J. de Smith (1 shared paper)Rachel Kerr (1 shared paper)David A. Anderson (1 shared paper)Eric Gardiner (3 shared papers)F. Lofts (3 shared papers)Joseph Sgouros (3 shared papers)
- Journals
- Journal of Clinical Oncology (3 papers)Cancer Chemotherapy and Pharmacology (2 papers)Clinical Cancer Research (1 paper)European Journal of Cancer (1 paper)Thrombosis Research (1 paper)
- Partner nations
- United KingdomUnited StatesGreece
In The Last Decade
D. Fyfe
14 papers receiving 1.4k citations
D. Fyfe's Hit Papers
Peers
Comparison fields: 5 of 97
- Internal Medicine 222
- Biochemistry 146
- Gastroenterology 91
- Oncology 341
- Emergency Medical Services 84
Countries citing papers authored by D. Fyfe
This map shows the geographic impact of D. Fyfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Fyfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Fyfe more than expected).
Fields of papers citing papers by D. Fyfe
This network shows the impact of papers produced by D. Fyfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Fyfe. The network helps show where D. Fyfe may publish in the future.
Co-authors
The 25 scholars most cited alongside D. Fyfe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Hit paper breakdown → | 1996 | 538 |
| 2 | Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial Hit paper breakdown → | 2013 | 413 |
| 3 | 2011 | 236 | |
| 4 | 1998 | 95 | |
| 5 | 2007 | 29 | |
| 6 | 2009 | 28 | |
| 7 | 2007 | 16 | |
| 8 | 2014 | 14 | |
| 9 | 2012 | 13 | |
| 10 | 2008 | 12 | |
| 11 | 2001 | 10 | |
| 12 | 2010 | 7 | |
| 13 | 2013 | 4 | |
| 14 | 2001 | 2 |
About D. Fyfe
D. Fyfe is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Molecular Biology and Dermatology, having authored 14 papers that have together received 1.4k indexed citations. Recurring topics across this work include Esophageal Cancer Research and Treatment (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Cancer Treatment and Pharmacology (3 papers), Gastric Cancer Management and Outcomes (3 papers), Lung Cancer Treatments and Mutations (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Venous Thromboembolism Diagnosis and Management (1 paper) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Internal Medicine (222 citations), Biochemistry (146 citations), Gastroenterology (91 citations), Oncology (341 citations) and Emergency Medical Services (84 citations). D. Fyfe has collaborated with scholars based in United Kingdom, United States and Greece. Frequent co-authors include D. Ferry, J Baker, Adam J. de Smith, Rachel Kerr, David A. Anderson, Eric Gardiner, F. Lofts, Joseph Sgouros, Anthony Maraveyas and K R Wedgwood. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Clinical Cancer Research, European Journal of Cancer and Thrombosis Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.